發(fā)布時(shí)間：2018-03-10 00:07

  本文選題：高管薪酬　切入點(diǎn)：企業(yè)績(jī)效　出處：《東華大學(xué)》2014年碩士論文　論文類(lèi)型：學(xué)位論文

【摘要】：長(zhǎng)期以來(lái),如何對(duì)高管人員進(jìn)行有效激勵(lì)一直是理論界和實(shí)務(wù)界關(guān)心的重要問(wèn)題。特別是股份公司大量興起之后,伴隨公司所有權(quán)與經(jīng)營(yíng)權(quán)的分離而產(chǎn)生的委托代理問(wèn)題,使高管人員激勵(lì)問(wèn)題受到了更廣泛的關(guān)注,激勵(lì)方式也得到了極大地發(fā)展。我國(guó)市場(chǎng)對(duì)激勵(lì)高管人員的探索實(shí)踐起步較晚,但最近幾年隨著公司治理的改進(jìn)以及資本市場(chǎng)的發(fā)展,高管人員獲得的激勵(lì)水平也開(kāi)始出現(xiàn)持續(xù)增長(zhǎng)。2006年初中國(guó)證監(jiān)會(huì)發(fā)布《上市公司股權(quán)激勵(lì)管理辦法》(試行),為我國(guó)上市公司廣泛開(kāi)展股權(quán)激勵(lì)鋪平了道路。在理論研究方面,國(guó)內(nèi)部分研究者對(duì)高管人員薪酬激勵(lì)、股權(quán)激勵(lì)與公司業(yè)績(jī)的關(guān)系進(jìn)行了初步的研究,取得了有益的成果,然而這些研究各自由于可能在數(shù)據(jù)選取、樣本挑選或統(tǒng)計(jì)方法使用等方面存在一些缺陷,因此仍然不夠完善。同時(shí),在薪酬激勵(lì)、股權(quán)激勵(lì)與公司業(yè)績(jī)關(guān)系這一課題之下還可以衍生出許多細(xì)分的研究方向,過(guò)往的研究也較少涉及。 有鑒于此,本文從Wind數(shù)據(jù)庫(kù)及CSMAR數(shù)據(jù)庫(kù)獲取上市醫(yī)藥公司數(shù)據(jù),運(yùn)用描述性統(tǒng)計(jì),多元回歸分析等方法重點(diǎn)研究了四個(gè)問(wèn)題,即：(1)高管薪酬激勵(lì)與上市醫(yī)藥企業(yè)業(yè)績(jī)的相關(guān)性(2)董事長(zhǎng)是否兼任總經(jīng)理對(duì)高管薪酬與上市醫(yī)藥企業(yè)業(yè)績(jī)的相關(guān)性的影響。(3)控股股東的類(lèi)型對(duì)高管薪酬與上市公司醫(yī)藥企業(yè)業(yè)績(jī)的相關(guān)性的影響。(4)不同薪酬激勵(lì)方式的效果是否存在差異。 研究發(fā)現(xiàn)：(1)總體而言,高管年薪與上市醫(yī)藥企業(yè)短期績(jī)效顯著正相關(guān),高管持股比例與上市醫(yī)藥企業(yè)長(zhǎng)期績(jī)效正相關(guān)。(2)相較而言,董事長(zhǎng)兼任總經(jīng)理會(huì)使得上市醫(yī)藥企業(yè)高管薪酬激勵(lì)作用有所下降。(3)目前我國(guó)上市醫(yī)藥國(guó)企與民企中,高管激勵(lì)效果差異并不顯著。(4)上市醫(yī)藥企業(yè)中,高管年薪對(duì)短期激勵(lì)更有效,而股權(quán)激勵(lì)則更適用于長(zhǎng)期激勵(lì)。
[Abstract]:For a long time, how to motivate executives effectively has been an important concern of the theoretical and practical circles, especially after the emergence of a large number of joint-stock companies, accompanied by the separation of corporate ownership and management of the principal-agent problem. As a result, the incentive problem of senior managers has been paid more attention to, and the incentive methods have been greatly developed. But in recent years, with the improvement of corporate governance and the development of capital markets, At the beginning of 2006, the China Securities Regulatory Commission issued the "measures on Stock incentive Management of listed companies", which paved the way for China's listed companies to widely carry out equity incentives. Some domestic researchers have made a preliminary study on the relationship between executive compensation incentive, equity incentive and corporate performance, and obtained useful results. However, these studies may be selected in the data. There are some defects in sample selection or the use of statistical methods, so it is still not perfect. At the same time, under the topic of compensation incentive, equity incentive and corporate performance relationship, there are still many subdivision research directions. Previous studies have also been less involved. In view of this, this article obtains the listed pharmaceutical company data from the Wind database and the CSMAR database, uses the descriptive statistics, the multivariate regression analysis and so on the method has studied the four questions emphatically, (1) the correlation between executive compensation incentives and the performance of listed pharmaceutical companies. (2) whether the chairman is concurrently the chairman of the board of directors on the relationship between executive compensation and the performance of listed pharmaceutical enterprises. 3) the type of controlling shareholders on the relationship between executive compensation and listed companies. The impact of the correlation of the performance of pharmaceutical companies. 4) whether there are differences in the effects of different compensation incentives. The study found that, in general, the annual executive salary was significantly positively correlated with the short-term performance of listed pharmaceutical companies, and the proportion of executive ownership was positively correlated with the long-term performance of listed pharmaceutical companies. The executive compensation incentive function of the listed pharmaceutical enterprises will be reduced by the chairman of the board of directors as the general manager.) at present, there is no significant difference in the effect of the executive incentive between the listed pharmaceutical state-owned enterprises and the private enterprises in our country) among the listed pharmaceutical enterprises, Annual executive pay is more effective for short-term incentives, while equity incentives are more suitable for long-term incentives.
【學(xué)位授予單位】：東華大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類(lèi)號(hào)】：F272.92;F426.72

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 邵平;劉林;孔愛(ài)國(guó);;高管薪酬與公司業(yè)績(jī)的敏感性因素分析——金融業(yè)的證據(jù)(2000～2005年)[J];財(cái)經(jīng)研究;2008年01期

2 李良智;夏靚;;上市公司管理層薪酬與公司績(jī)效的關(guān)系研究——以電子行業(yè)為樣本[J];當(dāng)代財(cái)經(jīng);2006年02期

3 盧銳;;管理層權(quán)力、薪酬與業(yè)績(jī)敏感性分析——來(lái)自中國(guó)上市公司的經(jīng)驗(yàn)證據(jù)[J];當(dāng)代財(cái)經(jīng);2008年07期

4 宋增基,張宗益;上市公司經(jīng)營(yíng)者報(bào)酬與公司績(jī)效實(shí)證研究[J];重慶大學(xué)學(xué)報(bào)(自然科學(xué)版);2002年11期

5 徐向藝;王俊椺;鞏震;;高管人員報(bào)酬激勵(lì)與公司治理績(jī)效研究——一項(xiàng)基于深、滬A股上市公司的實(shí)證分析[J];中國(guó)工業(yè)經(jīng)濟(jì);2007年02期

6 王克敏,陳井勇;股權(quán)結(jié)構(gòu)、投資者保護(hù)與公司績(jī)效[J];管理世界;2004年07期

7 張宏敏;單鑫;朱敏;;股票期權(quán)薪酬績(jī)效敏感度影響因素研究——基于股權(quán)分置改革后中國(guó)上市公司的實(shí)證分析[J];宏觀經(jīng)濟(jì)研究;2009年08期

8 李錫元;倪艷;;上市公司職業(yè)經(jīng)理人薪酬與企業(yè)績(jī)效關(guān)系的實(shí)證研究[J];經(jīng)濟(jì)管理;2007年06期

9 李燕萍;孫紅;;不同高管報(bào)酬方式對(duì)公司績(jī)效的影響研究——基于中國(guó)上市公司的經(jīng)驗(yàn)檢驗(yàn)[J];經(jīng)濟(jì)管理;2008年18期

10 朱紅軍;高級(jí)管理人員更換與經(jīng)營(yíng)業(yè)績(jī)[J];經(jīng)濟(jì)科學(xué);2004年04期

，

本文編號(hào)：1590868